ELIAS JOSEPH JABBOUR to Antibodies, Monoclonal, Humanized
This is a "connection" page, showing publications ELIAS JOSEPH JABBOUR has written about Antibodies, Monoclonal, Humanized.
Connection Strength
4.053
-
Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial. Lancet Haematol. 2020 Jul; 7(7):e523-e533.
Score: 0.334
-
Treatment of relapsed/refractory acute lymphoblastic leukemia. Clin Adv Hematol Oncol. 2019 Mar; 17(3):166-175.
Score: 0.305
-
Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage. Cancer. 2018 10 15; 124(20):4044-4055.
Score: 0.297
-
Therapeutic choices after hypomethylating agent resistance for myelodysplastic syndromes. Curr Opin Hematol. 2018 03; 25(2):146-153.
Score: 0.284
-
Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical Trial. JAMA Oncol. 2018 Feb 01; 4(2):230-234.
Score: 0.283
-
Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INO-VATE. Cancer. 2018 04 15; 124(8):1722-1732.
Score: 0.283
-
Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study. Lancet Oncol. 2018 02; 19(2):240-248.
Score: 0.282
-
Treatment of adult acute lymphoblastic leukemia with inotuzumab ozogamicin. Future Oncol. 2017 Oct; 13(25):2233-2242.
Score: 0.273
-
Inotuzumab ozogamicin in the treatment of acute lymphoblastic leukemia. Expert Rev Hematol. 2016; 9(4):329-34.
Score: 0.249
-
Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a CD22 monoclonal antibody. Am J Hematol. 2015 Mar; 90(3):193-6.
Score: 0.229
-
A phase 2a, single-arm, open-label study of tafasitamab, a humanized, Fc-modified, anti-CD19 antibody, in patients with relapsed/refractory B-precursor cell acute lymphoblastic leukemia. Cancer. 2021 11 15; 127(22):4190-4197.
Score: 0.090
-
Phase II study of azacitidine with pembrolizumab in patients with intermediate-1 or higher-risk myelodysplastic syndrome. Br J Haematol. 2021 11; 195(3):378-387.
Score: 0.090
-
Hyper-CVAD plus ofatumumab versus hyper-CVAD plus rituximab as frontline therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis. Cancer. 2021 09 15; 127(18):3381-3389.
Score: 0.089
-
Incorporating Immunotherapy Into the Treatment Strategies of B-Cell Adult Acute Lymphoblastic Leukemia: The Role of Blinatumomab and Inotuzumab Ozogamicin. Am Soc Clin Oncol Educ Book. 2018 May 23; 38:574-578.
Score: 0.072
-
Novel Therapies for Older Adults With Acute Lymphoblastic Leukemia. Curr Hematol Malig Rep. 2018 04; 13(2):91-99.
Score: 0.072
-
Patient-reported outcomes from a phase 3 randomized controlled trial of inotuzumab ozogamicin versus standard therapy for relapsed/refractory acute lymphoblastic leukemia. Cancer. 2018 05 15; 124(10):2151-2160.
Score: 0.071
-
Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: No change in the level of CD19 expression. Am J Hematol. 2018 03; 93(3):371-374.
Score: 0.070
-
Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study. Lancet Haematol. 2017 Aug; 4(8):e387-e398.
Score: 0.068
-
Minimal Residual Disease in Acute Lymphoblastic Leukemia: How to Recognize and Treat It. Curr Oncol Rep. 2017 Jan; 19(1):6.
Score: 0.066
-
Adult Acute Lymphoblastic Leukemia. Mayo Clin Proc. 2016 Nov; 91(11):1645-1666.
Score: 0.065
-
Role of inotuzumab ozogamicin in the treatment of relapsed/refractory acute lymphoblastic leukemia. Immunotherapy. 2016 Feb; 8(2):135-43.
Score: 0.061
-
A Phase II Study of Coltuximab Ravtansine (SAR3419) Monotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk. 2016 Mar; 16(3):139-45.
Score: 0.061
-
Inotuzumab ozogamicin in B-cell acute lymphoblastic leukemias and non-Hodgkin's lymphomas. Expert Opin Biol Ther. 2015 Apr; 15(4):601-11.
Score: 0.058
-
Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. Cancer. 2013 Aug 01; 119(15):2728-36.
Score: 0.051
-
Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2012 Aug; 12(4):244-51.
Score: 0.047
-
Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncol. 2012 Apr; 13(4):403-11.
Score: 0.047
-
Retrospective comparison of survival and responses to Fludarabine, Cytarabine, GCSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or Idarubicin (IDA) in patients with newly diagnosed core binding factor (CBF) acute myelogenous leukemia: MD Anderson experience in 174 patients. Am J Hematol. 2022 Nov; 97(11):1427-1434.
Score: 0.024
-
A phase 1b/2 study of azacitidine with PD-L1 antibody avelumab in relapsed/refractory acute myeloid leukemia. Cancer. 2021 10 15; 127(20):3761-3771.
Score: 0.022
-
Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations. Leukemia. 2021 12; 35(12):3421-3429.
Score: 0.022
-
Optimizing the use of the hyperCVAD regimen: Clinical vignettes and practical management. Cancer. 2020 03 15; 126(6):1152-1160.
Score: 0.020
-
Acute lymphoblastic leukemia in adolescents and young adults. Cancer. 2017 Jul 01; 123(13):2398-2403.
Score: 0.017
-
Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab. Blood. 2017 03 09; 129(10):1275-1283.
Score: 0.016
-
Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia. Am J Hematol. 2014 Oct; 89(10):964-8.
Score: 0.014
-
Failure of hypomethylating agent-based therapy in myelodysplastic syndromes. Semin Oncol. 2011 Oct; 38(5):682-92.
Score: 0.011
-
Gemtuzumab Ozogamicin is a promising post-remission therapy for acute myeloid leukemia. Leuk Res. 2009 Apr; 33(4):565-6.
Score: 0.009